Eris Biotech
Eris Biotech, based in American Fork, UT, is a healthcare company specializing in the development of hypoxia-activated prodrugs (HAPs) for treating solid tumors, with a focus on mesothelioma. The company aims to minimize side effects while maximizing effectiveness in cancer care.
Company Overview
Eris Biotech, founded in 2023, is a pioneering company in the healthcare industry focused on developing innovative cancer treatments. Based in American Fork, UT, USA, the company specializes in therapeutics, specifically targeting the tumor microenvironment to ensure maximum effectiveness with minimal side effects. Eris Biotech is part of the W24 batch of Y Combinator and operates primarily in the United States and Canada.
Innovative Cancer Treatments
Eris Biotech is at the forefront of revolutionizing cancer care by developing hypoxia-activated prodrugs (HAPs). These HAPs are designed to become active in hypoxic (low oxygen) environments typically found in solid tumors. This approach allows for targeted therapy that minimizes systemic toxicity, offering a promising treatment for various cancers. The company's beachhead market is mesothelioma, a rare cancer that currently has limited treatment options.
Therapeutic Focus
Eris Biotech is dedicated to crafting hope through the development of cutting-edge medicine. The company's primary focus is on creating therapeutic solutions that address the challenges of systemic toxicity in cancer treatment. By concentrating on the unique conditions within the tumor microenvironment, Eris Biotech aims to enhance the efficacy of cancer therapies while reducing adverse side effects.
Market and Expansion
Eris Biotech operates primarily in the United States and Canada. Although still in the early stages of development, the company is making significant strides in the field of oncology, with its innovative cancer treatment methods showing promise for future market expansion. As a participant in the W24 batch of Y Combinator, Eris Biotech is leveraging support and resources to further its mission of transforming cancer care.